A Global Phase 2 Randomized Double-Blind Placebo-Controlled Dose-Ranging Study of BMS-986177 an Oral Factor XIa Inhibitor for the Prevention of New Ischemic Stroke or New Covert Brain Infarction in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA)
Recruiting
99 years or below
All
Phase
2
15 participants needed
1 Location
Brief description of study
See full protocol for details.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
Updated on
14 Oct 2020.
Study ID: 831974